Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Pfizer Inc. announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the US District ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...

NEW YORK, June 24 /PRNewswire/ — Underscoring its commitment to scientific advancement, Pfizer Inc will launch Think Science Now, a science awareness program to promote exceptional researchers who ...

Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...

Pharmaceutical companies are keen to have a stake in the personalized medicine market, viewed as a growing trend in the future of healthcare and a significant source of life science innovation. As ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The Pfizer flu vaccine uses the same type of messenger RNA science that was used in the ...

Lisa Talbot, who served as chief client officer at 2025 MM+M Agency 100 honoree MSL, was named president of Spectrum Science ...